Neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD) are aging-related conditions. The prevalence of these conditions increases exponentially with the continuous growth in the elderly population. The broader personal, societal, and economic impact of AD and PD entail a huge economic burden to healthcare systems and severe impacts on the quality of life of the patients and their families. In the case of AD, studies show that many people currently living with dementia have not received a formal diagnosis of their condition.
In recent years, a large body of data has accumulated bringing in the light the pathophysiological factors underlying AD and OD. However, the treatments available for these neurodegenerative diseases are often no effective, have any disease-modifying effect or aim to address symptomatology by causing serious side effects.
In this Research Topic, Frontiers in Human Neuroscience is looking to address key aspects of the pathophysiology underlying AD and PD to promote the discussion around this topic and to facilitate knowledge dissemination in the field for early diagnosis and treatment.
We expect to attract significant contributions from diverse specialists in the field of AD and PD, to establish new trends for future studies.
We particularly welcome submission of original research, review, methods, and perspective articles on the following potential sub-topics:
- New insights on the mechanisms of the Alzheimer’s and Parkinson’s disease cause cognitive decline in patients
- New technological and behavioral methods in the early identification of Alzheimer’s and Parkinson’s disease symptomatology
- Evidences on the role of sex on cognition and behavior in Alzheimer’s and Parkinson’s disease
- Novel non-invasive biomarkers in disease diagnosis
- Behavioral, cognitive, and physical activity interventions that improve cognitive and motor symptomatology in neurodegenerative diseases
- Sleep in preclinical and early symptomatic Alzheimer's and Parkinson’s disease
- Advances in pharmacological/genetic treatments to ameliorate disease burden and progression
- Non-invasive neuromodulation and combined neurorehabilitation therapies for cognitive and psychiatric symptomatology in Alzheimer’s and Parkinson’s disease
- Digital health technologies for care of Alzheimer’s and Parkinson’s disease patients
LS is a PI in a phase II and a Phase III studies, sponsored by Biogen, that involve Alzheimer’s patients.
Neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD) are aging-related conditions. The prevalence of these conditions increases exponentially with the continuous growth in the elderly population. The broader personal, societal, and economic impact of AD and PD entail a huge economic burden to healthcare systems and severe impacts on the quality of life of the patients and their families. In the case of AD, studies show that many people currently living with dementia have not received a formal diagnosis of their condition.
In recent years, a large body of data has accumulated bringing in the light the pathophysiological factors underlying AD and OD. However, the treatments available for these neurodegenerative diseases are often no effective, have any disease-modifying effect or aim to address symptomatology by causing serious side effects.
In this Research Topic, Frontiers in Human Neuroscience is looking to address key aspects of the pathophysiology underlying AD and PD to promote the discussion around this topic and to facilitate knowledge dissemination in the field for early diagnosis and treatment.
We expect to attract significant contributions from diverse specialists in the field of AD and PD, to establish new trends for future studies.
We particularly welcome submission of original research, review, methods, and perspective articles on the following potential sub-topics:
- New insights on the mechanisms of the Alzheimer’s and Parkinson’s disease cause cognitive decline in patients
- New technological and behavioral methods in the early identification of Alzheimer’s and Parkinson’s disease symptomatology
- Evidences on the role of sex on cognition and behavior in Alzheimer’s and Parkinson’s disease
- Novel non-invasive biomarkers in disease diagnosis
- Behavioral, cognitive, and physical activity interventions that improve cognitive and motor symptomatology in neurodegenerative diseases
- Sleep in preclinical and early symptomatic Alzheimer's and Parkinson’s disease
- Advances in pharmacological/genetic treatments to ameliorate disease burden and progression
- Non-invasive neuromodulation and combined neurorehabilitation therapies for cognitive and psychiatric symptomatology in Alzheimer’s and Parkinson’s disease
- Digital health technologies for care of Alzheimer’s and Parkinson’s disease patients
LS is a PI in a phase II and a Phase III studies, sponsored by Biogen, that involve Alzheimer’s patients.
